RCMI Coordinating Center (RCMI CC) Header Logo

Connection

David Calhoun to Amiloride

Back to Details
This is a "connection" page, showing publications David Calhoun has written about Amiloride.
David Calhoun
Connection Strength
0.327
Amiloride
  1. Calhoun DA. Fluid retention, aldosterone excess, and treatment of resistant hypertension. Lancet Diabetes Endocrinol. 2018 06; 6(6):431-433.
    View in: PubMed
    Score: 0.159
  2. Judd EK, Calhoun DA, Warnock DG. Pathophysiology and treatment of resistant hypertension: the role of aldosterone and amiloride-sensitive sodium channels. Semin Nephrol. 2014; 34(5):532-9.
    View in: PubMed
    Score: 0.118
  3. Carter AR, Zhou ZH, Calhoun DA, Bubien JK. Hyperactive ENaC identifies hypertensive individuals amenable to amiloride therapy. Am J Physiol Cell Physiol. 2001 Nov; 281(5):C1413-21.
    View in: PubMed
    Score: 0.051
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support